Jean-Marie Cuillerot
Direttore Tecnico/Scientifico/R&S presso ACRIVON THERAPEUTICS, INC.
Provenienza dei contatti di primo grado di Jean-Marie Cuillerot
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 18 | |
Public Company | Biotechnology | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jean-Marie Cuillerot tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
ABIOMED, INC. | Medical Specialties | Director of Finance/CFO | |
GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal | |
IMMUNOMEDICS, INC. | Biotechnology | Director/Board Member | |
MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Director of Finance/CFO | |
ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member | |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Analyst-Equity | |
MILESTONE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
Metamark Genetics, Inc.
Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA. | Medical/Nursing Services | Chief Operating Officer Corporate Officer/Principal | |
TURG POIN | Pharmaceuticals: Major | Investor Relations Contact | |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Medical Specialties | Director/Board Member | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree | |
College of the Holy Cross (Massachusetts) | College/University | Undergraduate Degree | |
Leerink Partners LLC
Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Investment Banks/Brokers | Corporate Officer/Principal | |
B. Riley Securities, Inc.
B. Riley Securities, Inc. Investment Banks/BrokersFinance B. Riley Securities, Inc. is a registered broker/dealer headquartered in Los Angeles, California. The firm is a subsidiary of B. Riley Securities Holdings LLC, ultimately owned by B. Riley Financial, Inc. (NASDAQ: RILY). The firm was formed in 2017, when B. Riley Financial, Inc. merged two of their brokers, B. Riley & Co. (founded in 1997) and FBR Capital Markets & Co. (founded in 1989), under the name of B. Riley FBR, Inc. B. Riley Securities provides research and trading ideas to institutional clients and high net-worth individuals. They provide investment banking services to a wide range of middle-market private and public companies. | Investment Banks/Brokers | Analyst-Equity | |
MIRATI THERAPEUTICS | Biotechnology | Chief Executive Officer | |
Yale University | College/University | Graduate Degree | |
University of Wisconsin | College/University | Undergraduate Degree | |
University of Illinois | College/University | Doctorate Degree | |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Pharmaceuticals: Major | Director/Board Member | |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Lund | College/University | Doctorate Degree | |
University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
ALAUNOS THERAPEUTICS, INC. | Biotechnology | Investor Relations Contact | |
General Electric Healthcare Technologies, Inc.
General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Medical/Nursing Services | Corporate Officer/Principal | |
BTIG LLC
BTIG LLC Investment Banks/BrokersFinance BTIG LLC is an institutional brokerage and fund services firm headquartered in San Francisco, California. The firm was founded in 2002 through the merger of Baypoint Trading LLC and Bass Trading LLC. They are a subsidiary of Condor Trading LP. BTIG offers institutional and corporate clients with personalized multi-asset class execution, expertise and insights worldwide across equities, equity derivatives, ETFs, fixed income, futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities. The firm’s core capabilities include global sales, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. | Investment Banks/Brokers | Analyst-Equity | |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Pharmaceuticals: Major | Director/Board Member | |
The Lexington
The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The company is based in Ventura, CA. | Medical/Nursing Services | Director of Finance/CFO | |
Motorola Automotive & Industrial Electronics Group | Corporate Officer/Principal | ||
XTuit Pharmaceuticals, Inc.
XTuit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology XTuit Pharmaceuticals, Inc. develops drugs for the treatment of cancer. The firm develops pharmaceutical products for use in the diagnosis and treatment of oncological, tumor and inflammatory diseases. The company was founded by Alan L. Crane, Rakesh Kumar Jain, Andrew Werk Cook, Edwin L. Steele, David H. Koch, Ronald Evans, Howard Hughes and Robert S. Langer, Jr. in 2011 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Kellogg School of Management | College/University | Masters Business Admin | |
Washington University School of Medicine | College/University | Doctorate Degree | |
CRISPR THERAPEUTICS AG | Biotechnology | Director of Finance/CFO | |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Packaged Software | Chairman | |
PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Packaged Software | Director/Board Member | |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
POSEIDA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
89BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Packaged Software | Director/Board Member | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Biotechnology | Director/Board Member | |
ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
ZAI LAB LIMITED | Biotechnology | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
Stati Uniti | 43 |
Svizzera | 3 |
Canada | 2 |
Svezia | 2 |
Danimarca | 2 |
Settori
Health Technology | 26 |
Consumer Services | 11 |
Finance | 7 |
Health Services | 4 |
Technology Services | 4 |
Posizioni
Director/Board Member | 61 |
Corporate Officer/Principal | 36 |
Independent Dir/Board Member | 30 |
Director of Finance/CFO | 16 |
Chief Tech/Sci/R&D Officer | 14 |
Contatti più connessi
Insiders | |
---|---|
Mohammed Malik | 24 |
Ivana Magovcevic-Liebisch | 18 |
Derek DiRocco | 17 |
Charles Ballantyne | 15 |
Michael Tomsicek | 12 |
Charles Baum | 12 |
Marc van Dijk | 9 |
Eric Devroe | 8 |
Peter Blume-Jensen | 8 |
Adam Levy | 8 |
Mary Miller | 8 |
Justin Zelin | 6 |
Sharon Shacham | 5 |
Erick Gamelin | 4 |
Rasmus Holm-Jorgensen | 4 |
- Borsa valori
- Insiders
- Jean-Marie Cuillerot
- Connessioni Società